Patent US4764369A successfully refreshed from Google Patents.
US4764369A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Undenatured virus-free biologically active protein derivatives
Assignee: New York Blood Center
•
Filing: 1984-07-17
•
Granted: 1988-08-16
•
Expires: 2004-07-17
Abstract
Abstract A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
Inventors
- 👤 Alexander R. Neurath
- 👤 Bernard Horowitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 12:38
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/02; A61L2/04; A61L2/16; A61L2/18; A61L2103/00; A61L2103/05
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
52 words
A labile protein-containing composition having once been lipid coated virus infected and thereafter treated so as to have an extent of inactivation of lipid coated-containing virus greater than 4 logs of said virus and wherein the amount of active non-virus labile protein relative to total non-virus labile protein is at least 80%.
Claim 2
Dependent Claim
52 words
A labile protein-containing composition having once been lipid coated virus infected and thereafter treated so as to have an extent of inactivation of lipid coated-containing virus greater than 4 logs of said virus and wherein the amount of active non-virus labile protein relative to total non-virus labile protein is at least 80%.
Claim 3
Dependent Claim
21 words
A protein-containing composition according to claim 1 wherein the amount of active protein relative to total protein is at least 85%.
Claim 4
Dependent Claim
21 words
A protein-containing composition according to claim 1 wherein the amount of active protein relative to total protein is at least 95%.
Claim 5
Dependent Claim
24 words
A protein-containing composition according to claim 1 wherein the amount of active protein relative to total protein is between about 98% and about 100%.
Claim 6
Dependent Claim
25 words
A protein-containing composition according to claim 1 which is a product of a non-blood normal or cancerous cell comprising an active protein and inactivated virus.
Claim 7
Dependent Claim
15 words
A protein-containing composition according to claim 1, wherein the composition is a blood protein-containing composition.
Claim 8
Dependent Claim
42 words
A protein-containing composition according to claim 6 wherein said protein-containing composition is selected from the group consisting of whole blood, blood plasma, plasma concentrate, precipitate from any fractionation of such plasma, supernatant from any fractionation of said plasma, serum, cryoprecipitate and cryosupernatant.
Claim 9
Dependent Claim
11 words
A protein-containing composition according to claim 6 which comprises factor VIII.
Claim 10
Dependent Claim
11 words
A protein-containing composition according to claim 6 which comprises factor IX.
Claim 11
Dependent Claim
10 words
A protein-containing composition according to claim 6 which comprises immunoglobulins.
Claim 12
Dependent Claim
17 words
A process according to claim 1 wherein said composition is substantially free of infective lipid coated-containing viruses.
Claim 13
Dependent Claim
10 words
A protein-containing composition according to claim 6, which comprises fibronectin.
Claim 14
Dependent Claim
61 words
A protein-containing composition according to claim 1, wherein said protein-containing composition is derived from a virus infected protein-containing composition and subjected to a viral inactivation process comprising contacting the virus infected composition with an effective amount of di- or trialkylphosphate for a sufficient period of time to render the composition substantially free of lipid coated-containing viruses, without incurring substantial protein denaturation.
Claim 15
Dependent Claim
13 words
A protein-containing composition according to claim 13, wherein the trialkylphosphate is tri-n-butyl phosphate.
Claim 16
Dependent Claim
14 words
A protein-containing composition according to claim 13, wherein the virus is hepatitis B virus.
Claim 17
Dependent Claim
17 words
A protein-containing composition according to claim 13, wherein the virus is non A, non B hepatitis virus.
References Cited (Backward Citations)
US3686395A
Cited
US3655871A
Cited
US3674864A
Cited
US4070454A
Cited
US3962421A
Cited
US4105650A
Cited
US4168300A
Cited
US4350707A
Cited
US4057628A
Cited
US4206014A
Cited
US4222934A
Cited
US4349539A
Cited
US4305871A
Cited
US4370264A
Cited
US4315919A
Cited
EP0050061A2
Cited
US4314997A
Cited
US4404187A
Cited
US4405603A
Cited
US4424206A
Cited
US4438098A
Cited
US4481189A
Cited
US4581231A
Cited
US4434093A
Cited
US4534972A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-16 | 1992-02-15 | 1992-08-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-16 | 1996-02-15 | 1996-08-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-16 | 2000-02-15 | 2000-08-16 | $7700.00 | Window Closed / Lapsed |